Go Symbol Lookup
Loading...

Health Care

More

  • Waking Up to Sleep Apnea Tuesday, 1 Jul 2008 | 6:28 PM ET

    Well, figuring out how to profit off it, anyway. Here’s Cramer’s pick.

  • Prescription for Profits Tuesday, 1 Jul 2008 | 6:28 PM ET

    Allscripts could see tremendous growth when a new Medicare bill is passed.

  • Abbott, Boston Scientific Stents & Stuff Tuesday, 1 Jul 2008 | 10:33 AM ET
    Heart Stent

    So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4.

  • Making Money Off Medicare Monday, 30 Jun 2008 | 6:05 PM ET

    Fresenius might cash in once the new bill passes.

  • Medicare Matters Monday, 30 Jun 2008 | 6:00 PM ET

    Some lucky companies will split up $454 billion this year. But who?

  • A "Short" Story On Amgen Monday, 30 Jun 2008 | 9:04 AM ET
    AMGEN

    When combing through Barron's over the weekend I always make it a point to check out the "Short Interest" tables when they appear. I'm curious, in particular, about the ups and downs in Dendreon. Right now it's 39th on Barron's list of the Top-40 largest short positions.

  • Merck Muscles In On Migraines Friday, 27 Jun 2008 | 4:29 PM ET

    On another ugly day for the stock markets, beaten down shares of Dow component Merck rallied. The stock started picking up steam after the news broke late this morning that its late-stage experimental migraine headache drug essentially works just as well as an existing drug, but with fewer side effects.

  • Fourth of July fireworks

    FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."

  • sCredit Suisse building sign

    Credit Suisse is out today with a "fat" report on obesity. Nearly 200 pages. But besides its size, the research also stands out as one of the most unique pieces of Wall Street analysis I've ever seen.

  • Roche to Let Businesses Reserve Tamiflu Stockpiles Thursday, 26 Jun 2008 | 1:38 PM ET

    A new kind of contract, which would be renewed each year, will allow companies to buy a full shipment of Tamiflu at the prevailing wholesale price.

  • FDA Delivers One-Two Punch To Merck & Lilly Wednesday, 25 Jun 2008 | 11:11 AM ET
    FDA

    For the second time in three days the Food and Drug Administration has delayed making a decision on drugs that it had put on a fast track. First, the agency put off a ruling on Lilly's bloodthinner Effient and then this morning Merck announced the FDA is not ready to approve its cervical cancer vaccine Gardasil for older women.

  • Lilly's Effient Empire Tuesday, 24 Jun 2008 | 10:49 AM ET

    Tree huggers (just a colloquialism, not a dig) will be glad to know that biopharmaceutical companies submit their Food and Drug Administration filings for drug approval electronically these days.

  • Pfizer and the State of Statins Monday, 23 Jun 2008 | 11:15 AM ET

    As much as I tried to disconnect during my vacation last week, I couldn't escape the ubiquitous presence of pharmaceuticals in our everyday lives...

  • You need health insurance, period. So why do employers make it so painstaking to figure out?

  • Lance Armstrong And Livestrong.com: Will It Work? Tuesday, 17 Jun 2008 | 9:59 AM ET
    Lance Armstrong

    Lance Armstrong is among the most relevant retired athletes, having raised tens of millions of dollars for cancer research through his foundation. His slogan "Livestrong" has been featured on everything from those familiar yellow bracelets to a whole line of Nike product, in which 100 percent of the profits go to charity.

  • Pfizer, Avant, Wyeth And Elan: Your Emails Friday, 13 Jun 2008 | 10:55 AM ET

    It never ceases to amaze me who reads Pharma's Market. Like the Stanford University professor who wrote to set the record straight regarding my coverage from ASCO of the brain cancer vaccine from Pfizer and Avant.

  • Wyeth & Elan Are Real Hot Topic At Investor Meeting Thursday, 12 Jun 2008 | 3:18 PM ET

    I'm at the Needham & Company biotech conference in New York City. Whenever possible I like to attend events like this. It's a good place to get story ideas. The Needham meeting is competing this year with a similar one being put on by Goldman Sachs in Laguna Beach, CA.

  • Pfizer Gets Two Opinions Thursday, 12 Jun 2008 | 10:13 AM ET

    Pfizer shares continue to trade at new nearly 11-year lows over concerns the dividend might get cut, in addition to the lack of anything visible to replace Lipitor when it goes generic in a couple years or so. But on two of the op-ed pages in Wednesday's "Wall Street Journal" Pfizer got a plug.

  • Wyeth and Elan Face Big Test Wednesday, 11 Jun 2008 | 12:29 PM ET
    Wyeth

    Cancer, diabetes and Alzheimer's Disease. Three of the biggest areas of unmet medical need have been or will be in focus at a series of important scientific meetings in June or July.

  • Is Lilly & Amylin's Byetta "Betta"? Tuesday, 10 Jun 2008 | 1:28 PM ET
    To the right of Mike is HDL or "good" cholesterol. To his left in green is a triglyceride. The photo was taken at the booth for the diabetes drug Actos on the exhibit floor at the ADA meeting at Moscone Center in San Francisco.

    First, last Friday, Novo Nordisk put out a press release saying preliminary data show its drug works better than Byetta. And then, yesterday an analyst downgraded the stock just ahead of the company's long anticipated release of long-term results on its once-a-week version of Byetta.